Results 61 to 70 of about 42,119 (250)
Van Tıp Dergisi, 2022 Amiodarone is an effective anti-arrhythmic agent widely used for management of supraventricular and ventricular arrhythmias. Amiodarone-induced pulmonary toxicity is one of the most serious side effects of amiodarone therapy.
Nuri Köse, Tarık Yıldırım
doaj +1 more source
The Effects of Amiodarone on the Thyroid* [PDF]
Endocrine Reviews, 2001 Amiodarone is a benzofuranic-derivative iodine-rich drug widely used for the treatment of tachyarrhythmias and, to a lesser extent, of ischemic heart disease. It often causes changes in thyroid function tests (typically an increase in serum T(4) and rT(3), and a decrease in serum T(3), concentrations), mainly related to the inhibition of 5'-deiodinase ...
MARTINO, ENIO +3 more
openaire +4 more sources
Phytotherapy Research, EarlyView.Schematic representation of the shared pathophysiological mechanisms underlying heart failure (HF) and atrial fibrillation (AF), including inflammation, oxidative stress, endothelial dysfunction, and fibrosis. The figure highlights the clinical and mechanistic convergence of conventional pharmacological therapies and selected nutraceuticals in ...
Laura Beatrice Mattioli +6 more
wiley +1 more source
, 2003 2003-12Antiarrhythmic effects of long-term amiodarone is supposed to be mediated in part by cardio-selective hypothyroidism, but the issue remains controversial.
Miwa, Keiko +7 more
core +1 more source
Journal of Pharmaceutical Health Care and Sciences, 2018 Background Amiodarone and warfarin are sometimes administered immediately after cardiac surgery. Although the interaction between long-term oral amiodarone and warfarin has been reported, the interaction between warfarin and short-term intravenous ...
Tomoki Takase +6 more
doaj +1 more source
Cardiotoxicity of BRAF/MEK inhibitors
British Journal of Pharmacology, EarlyView.Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe +4 more
wiley +1 more source
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
British Journal of Pharmacology, EarlyView.Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
Neuroprotective effects of amiodarone in a mouse model of ischemic stroke
BMC Anesthesiology, 2017 Background Ion channels play a crucial role in the development of ischemic brain injury. Recent studies have reported that the blockade of various types of ion channels improves outcomes in experimental stroke models.
Masakazu Kotoda +4 more
doaj +1 more source
Respirology Case Reports, 2023 Amiodarone is a commonly used antiarrhythmic agent but exhibits potential pulmonary toxicity. In this case series, we describe the clinical, radiographic, and histologic manifestations of three patients who developed interstitial lung disease (ILD ...
I‐Lin Tsai +4 more
doaj +1 more source
Bruton tyrosine kinase inhibitors and cardiovascular adverse events
British Journal of Pharmacology, EarlyView.Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli +4 more
wiley +1 more source